Recently, the online seminar “Expanding into the Russian Pharmaceutical Market with Experts” was successfully convened, focusing on market entry strategies for the Russian pharmaceutical sector. Hosted via Zoom, the event was jointly organized by TAAL Healthtech, Zhonglun W&D Law Firm’s Chengdu Office, and Qianhai Office. The seminar featured authoritative experts including Chief Assistant Maria Timofeeva, Senior Consultant Qi Kang of Zhonglun W&D Chengdu Office, Partner Alexander Averbuch, Corporate in-house legal counsel Ekaterina Shilovskaya, and Partner Yuliya Dvornikova, attracting numerous pharmaceutical industry professionals and legal experts to gather virtually and pool insights for expanding into the Russian market. 

At the outset, the host outlined the seminar’s background and core objectives, emphasizing the vast potential of the Russian pharmaceutical market amid global industry trends and the urgent need for Chinese pharmaceutical companies to explore overseas opportunities. Subsequently, Ms. Qi Kang, Senior Consultant at Zhonglun W&D Chengdu Office, delivered an in-depth presentation on “China’s Restrictions and Controls on the Export of Medical Products”. She systematically analyzed the roles of regulatory bodies such as the National Medical Products Administration (NMPA), provincial medical products administrations, the Ministry of Commerce, and Customs, as well as the laws and regulations applicable to the export of medical products, including national laws like the “Drug Administration Law of the People’s Republic of China” and “Foreign Trade Law of the People’s Republic of China”, alongside departmental regulations, draft for comments, and local guidelines.

Experts highlighted that understanding China’s drug export regulatory system is fundamental for companies seeking compliant market entry into Russia. Clear regulatory processes and compliance guidelines can help mitigate risks and facilitate smooth export operations. Additionally, tailored strategies are needed to address Russia’s market-specific requirements, including regulatory alignment, market access, and partnership models.

During the seminar, co-hosts from various institutions engaged in lively discussions with attendees, exchanging insights on practical challenges, policy updates, and market opportunities in Sino-Russian pharmaceutical trade. Participants praised the event for its substantive content, noting that it clarified export regulations while providing actionable strategies for market expansion. Many expressed hopes for future collaborations to propel Chinese pharmaceutical companies to thrive in the Russia market. 

The successful seminar served as an effective platform for Sino-Russian pharmaceutical cooperation, offering valuable policy interpretations, market insights, and resource networking. Leveraging its deep expertise in pharmaceutical law, Zhonglun W&D Law Firm provided comprehensive compliance support and strategic guidance for companies venturing overseas.

Moving forward, Zhonglun W&D Law Firm will continue to empower Chinese pharmaceutical enterprises in their expansion into the Russian market, driving Sino-Russian pharmaceutical trade cooperation to new heights.